Accord Healthcare's Imuldosa® Biosimilar Receives Positive CHMP Opinion
Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals, has exciting news regarding its biosimilar product, Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®. This significant development marks a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Impact of Imuldosa® on Accord's Portfolio
This recommendation is a pivotal step for Accord as it enhances the company's growing biosimilar portfolio. With Imuldosa®, Accord solidifies its Autoimmune Franchise, building upon its existing top-selling brands. Following this addition, Imuldosa® will become the fifth biosimilar in Accord's European lineup, with ten more biosimilars currently in different stages of development.
The Importance of Ustekinumab
Ustekinumab is a human monoclonal antibody that effectively targets interleukin-12 and interleukin-23, which are crucial in managing inflammatory conditions and immune responses. The promising data surrounding Imuldosa® illustrates not only its potential for patients needing effective treatments but also its role in providing more options within the immunology market.
Statements from Accord's Executive Team
In response to this positive opinion, Paul Tredwell, Executive Vice President of Accord Healthcare, expressed his enthusiasm, stating, "We are delighted with the positive CHMP opinion for Imuldosa®. This further strengthens our established autoimmune franchise, where Accord already has several leading specialty brands. The recommendation affirms Accord's continued strategy to expand its speciality business with an industry-leading portfolio of innovative treatments. This positive opinion, alongside ten biosimilars under development, underscores our ongoing commitment to improving patient access to value-based medicines globally."
Binish Chudgar, Executive Chairman and Managing Director of Intas Pharmaceuticals Ltd, echoed this sentiment, emphasizing their dedication to enhancing global access to essential medicines through strategic partnerships and advancements in their biosimilar offerings.
Clinical Evidence Supporting the Biosimilar
The EMA CHMP's positive opinion for Imuldosa® is backed by robust clinical evidence demonstrating its similarity to the reference product, Stelara®. DMB-3115 has shown comparable quality, safety, and efficacy based on clinical trials, including a pivotal phase III multi-regional study focusing on plaque psoriasis.
The results from this trial indicate that DMB-3115 offers a similar safety and efficacy profile to Stelara®, suggesting it can serve as an effective alternative for patients requiring treatment for various immunological conditions.
The Market Landscape
Stelara®, known for its effectiveness in treating several immunology-related conditions, has amassed significant sales figures worldwide, with recent reports indicating approximately $19 billion in global revenue and around $3.2 billion in Europe alone. This robust market presence highlights the potential opportunity for Imuldosa® within the landscape of immunology treatments.
Looking Forward
With Imuldosa®'s journey toward marketing authorization progressing positively, Accord Healthcare continues to pave the way for broader access to innovative treatments for patients suffering from chronic conditions. The commitment of Accord to produce high-quality biosimilars underlines its strategic vision to meet the evolving needs of healthcare systems globally.
Frequently Asked Questions
What is Imuldosa®?
Imuldosa® is a biosimilar to Stelara® (ustekinumab), developed by Accord Healthcare, targeting immune-mediated conditions.
What does a positive CHMP opinion mean for Imuldosa®?
A positive CHMP opinion indicates that the EMA recommends marketing authorization, suggesting that the product meets necessary safety and efficacy standards.
How many biosimilars does Accord Healthcare currently have?
With the addition of Imuldosa®, Accord Healthcare will have five biosimilars in the EU market, along with ten more in development.
What is the significance of tackling interleukin-12 and interleukin-23?
Targeting these cytokines is crucial in managing inflammatory and immune responses in conditions like psoriasis and Crohn's disease.
What are the next steps for Accord Healthcare with Imuldosa®?
Accord Healthcare will continue its efforts toward finalizing marketing authorization and preparing for market launch following the positiveCHMP opinion.
